Subject: Metalert embarks on strategic integration of AI into wearable healthcare technologies

MetAlert announced its visionary advance into AI-driven healthcare. Initiating a series of RFPs and detailed discussions with potential developers and

PRESS RELEASE

8.21.2023

METALERT EMBARKS ON STRATEGIC INTEGRATION OF AI INTO WEARABLE HEALTHCARE TECHNOLOGIES

LOS ANGELES, CALIFORNIA, August 21, 2023 -- MetAlert, Inc. (OTC: MLRT), a pioneer in location sensitive health monitoring devices and wearable technology healthcare solutions, today announced its visionary advance into AI-driven healthcare. Initiating a series of RFPs and detailed discussions with potential developers and strategic partners, the Company is signaling its vision to incorporate groundbreaking capabilities of artificial intelligence into its various technology platforms, marking this a critical pivot for the wearable healthcare sector, and commitment to fully harness the potential of artificial intelligence to help shape the future of healthcare.


Positioned to capitalize on an industry expected to reach a staggering $63 billion by 2025, MetAlert is undertaking more than just the enhancement of its remote patient monitoring solutions. This major step signifies the management's strong belief that integrating AI into its products that are currently collecting data across the globe, is a pathway forward for laying down the foundation to predictive healthcare.

Key to this strategy is MetAlert's suite of wearable technologies, specifically the patented GPS SmartSole® and the RoomMate 3D infrared fall detection system. Designed to capture data in real-time, this data will soon interface with an AI system in order to provide predictive analytics. The aim? A deeper insight into health patterns, timely alerts concerning potential health disturbances, and a proactive stance in potentially thwarting major medical incidents before they occur. What if by utilizing all this data in conjunction with A.I. we can determine or predict outcomes, discern health trajectories, alert to potential medical threats, and perhaps preempt significant medical events.


With management fully dedicated, MetAlert is actively seeking collaborations and evaluating state-of-the-art technologies. The mission? Crafting innovative, patentable software algorithms, fueled by MetAlert’s data that will position MetAlert as a key provider in the AI-enhanced wearable tech industry.


Patrick Bertagna, CEO of MetAlert, commented, "Wearable technology devices are collecting data in real time all over the world, and adding AI into our technological foundations isn't merely an evolution—it's a declaration of our vision, mission and goals to unleash our full value proposition. Our trajectory isn't just about keeping pace with wearable tech advancements; it's about setting our sights on transforming healthcare, delivering a better quality and longevity of life, championing a vision for a healthier, interconnected world and maximizing value for our stakeholders."


To find out more how you can buy or become an authorized reseller or partner please contact info@metalert.com business development.

About MetAlert 

MetAlert (OTC: MLRT) and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling, and licensing products, services, and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. With over 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with Alzheimer, dementia, and autism. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software, and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low power consumption GPS, Cellular, RF, NFC, and BLE technologies, enabling caregivers to track and monitor patients in real time. Known for its game-changing and award-winning patented GPS SmartSole® -- think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers across the globe with subscribers in over 40 countries and is a U.S. Military Government contractor. Other customers include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. www.MetAlert.com 

#knowledgeishealth #withyou #smartsole #connectedandprotected #trackwhatyoulove #wearabletech

#iot #nfc #gps #safety #healthcare #veritap #assettracking

 

General information, investor relations, wholesale licensing, consumer purchase:

213.489.3019  | Info@metalert.com | IR@metalert.com | Contact Us

United Kingdom Office: Nelson Skip Riddle | NSRiddle@metalert.com | +44 7785 364100

Forward Looking Statements

This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and its perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are set forth in MetAlert‘s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not place undue reliance on GTX’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.

Disclaimer: MetAlert, formerly GTX Corp, does not warrant or represent that the unauthorized use of materials drawn from the content of this document will not infringe rights of third parties who are not owned or affiliated by MetAlert. Further MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.